Share Article
-- Companies to Pursue a Human Genetics Approach to Drug Discovery and Development --
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190508005070/en/
Under the multi-year collaboration, Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch’s proprietary Kidney Genome Atlas™ (KGA), a comprehensive registry of patients with kidney diseases integrating genomic, transcriptomic and proteomic data with patient clinical profiles. In addition, Goldfinch will apply its biology platform of human induced pluripotent stem cell-derived kidney cells and kidney organoids to validate targets and support discovery and development of products to which Gilead will have exclusive option rights.
Through sequencing the DNA of a large cohort of diabetic patients with and without kidney disease, Goldfinch will expand the scope of the KGA beyond orphan kidney diseases to include DKD. In addition to target identification and validation, Goldfinch will lead discovery and development activities prior to exercise of exclusive option rights by Gilead, at which time Gilead will be responsible for the development and commercialization of optioned products. Goldfinch retains the option to lead development and co-promote optioned products directed to specific kidney disease targets. The collaboration does not include Goldfinch’s existing programs, GFB-887 and GFB-024, for which Goldfinch will retain all rights.
“We are excited to partner with
“Goldfinch has established unique genetic and biology platforms that
will allow for the identification and validation of novel targets for
kidney disease and for the discovery and development of novel
compounds,” said John McHutchison, AO, MD, Chief Scientific Officer and
Head of Research and Development at
Under the terms of the agreement, Goldfinch will receive
About Diabetic Kidney Disease
Diabetic kidney disease (DKD) develops in approximately 30-40 percent of patients who have diabetes and is a leading cause of end-stage kidney disease, cardiovascular disease and early mortality worldwide. Despite current therapies, the number of people with DKD continues to increase, highlighting the need for additional treatments that preserve kidney function.
About Gilead Sciences
About Goldfinch Bio
Goldfinch Bio is a biotechnology company that is singularly focused on
discovering and developing precision therapies for patients with kidney
diseases. Just as the goldfinch has long been a symbol of healing and
renewal and was a prominent figure of the Renaissance, Goldfinch Bio is
leading a new age of therapeutic discovery to transform the treatment
paradigm for patients with kidney diseases. Goldfinch was launched in
2016 by
Gilead Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the risk
that the parties may not realize the potential benefits of this
collaboration, and Gilead may fail to discover, develop and
commercialize any product candidates for the treatment of diabetic
kidney disease and other kidney diseases. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. These risks, uncertainties and other factors
could cause actual results to differ materially from those referred to
in the forward-looking statements. The reader is cautioned not to rely
on these forward-looking statements. These and other risks are described
in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005070/en/
Source:
Gilead Contacts:
Sung Lee, Investors(650) 524-7792
Nathan Kaiser, Media(650) 522-1853
Goldfinch Contacts:
Michael Broxson, Investors617-337-4200mbroxson@goldfinchbio.com
Gina Nugent, Media617-460-3579gina@theyatesnetwork.com
Other News
Some of the content on this page is not intended for users outside the U.S.